1. Clinical & Scientific Overview
Solifenacin Succinate (TIP-MED-000235, Reference Code [12.3]) is classified under
Urological & Renal Stone Medicines (Ch 12) as a Urinary Bladder-Selective Muscarinic M3-Receptor Antagonist (Anticholinergic Bladder Spasmolytic).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.3], p. 156): Soliten (Ranbaxy/Sun Pharma), Vesicare (Astellas), Bispec (Dr. Reddy's), Solicept (Lupin), Flotros — Strengths & Dosage Forms: Oral Film-Coated Tablets: 5 mg, 10 mg
Oral Film-Coated Tablets: 5 mg, 10 mg
3. Mechanism of Action & Pharmacodynamics
Urinary Bladder-Selective Muscarinic M3-Receptor Antagonist (Anticholinergic Bladder Spasmolytic) acting on target receptor/enzyme pathways in Urological & Renal Stone Medicines (Ch 12): clinical efficacy is mediated via Urinary Bladder-Selective Muscarinic M3-Receptor Antagonist (Anticholinergic Bladder Spasmolytic) for Overactive Bladder (OAB) and Detrusor Overactivity presenting with urinary urgency, frequent daytime/nocturnal urination (pollakiuria/nocturia), and urge urinary incontinence..
4. Therapeutic Indications & Evidence-Supported Uses
- Overactive Bladder (OAB) and Detrusor Overactivity presenting with urinary urgency, frequent daytime/nocturnal urination (pollakiuria/nocturia), and urge urinary incontinence
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: 5 mg once daily; if needed and well tolerated, may be increased to 10 mg once daily (Maximum 5 mg once daily in severe renal impairment or moderate hepatic impairment, or with potent CYP3A4 inhibitors). Follow urologist prescription.
Administration & Meal Timing: With or without food, swallowed whole with water. | Once daily (morning or evening; very long elimination half-life of 45–68 hours provides 24-hour bladder relaxation).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Dosing depends on severe renal impairment! In severe CKD (CrCl ≤30 mL/min), exposure increases by 2.1-fold—do NOT exceed 5 mg once daily! Hepatic: In moderate hepatic impairment (Child-Pugh B), do not exceed 5 mg once daily; contraindicated in severe hepatic impairment (Child-Pugh C).
Renal: Dosing depends on severe renal impairment! In severe CKD (CrCl ≤30 mL/min), exposure increases by 2.1-fold—do NOT exceed 5 mg once daily! Hepatic: In moderate hepatic impairment (Child-Pugh B), do not exceed 5 mg once daily; contraindicated in severe hepatic impairment (Child-Pugh C).
Renal: Dosing depends on severe renal impairment! In severe CKD (CrCl ≤30 mL/min), exposure increases by 2.1-fold—do NOT exceed 5 mg once daily! Hepatic: In moderate hepatic impairment (Child-Pugh B), do not exceed 5 mg once daily; contraindicated in severe hepatic impairment (Child-Pugh C).
7. Contraindications, Precautions & High-Risk Warnings
- Strictly CONTRAINDICATED in Urinary Retention (or high Post-Void Residual [PVR] urine volume >150–200 mL in unoperated BPH!), Uncontrolled Narrow-Angle Glaucoma, Myasthenia Gravis, Severe Gastrointestinal Conditions (toxic megacolon, gastric retention, bowel obstruction), Haemodialysis, Severe Hepatic Impairment, and QTc Prolongation!
Key Clinical Precautions: Renal: Dosing depends on severe renal impairment! In severe CKD (CrCl ≤30 mL/min), exposure increases by 2.1-fold—do NOT exceed 5 mg once daily! Hepatic: In moderate hepatic impairment (Child-Pugh B), do not exceed 5 mg once daily; contraindicated in severe hepatic impairment (Child-Pugh C).
8. Adverse Effects Profile
- Dry mouth (xerostomia, 11% at 5 mg, climbing to 28% at 10 mg!), Constipation (5–13%), Blurred vision (accommodation cycloplegia), dry eyes, dyspepsia, urinary tract infection (due to incomplete bladder emptying).
- Acute Urinary Retention (especially in elderly men with concurrent BPH!), Anticholinergic Cognitive Impairment, Confusion, Memory Loss, Hallucinations, and Delirium in Elderly Patients (especially those with dementia or Parkinson's!), QTc Interval Prolongation and Torsades de Pointes, heat stroke / anhidrosis (reduced sweating during extreme Indian summer heat waves!), faecal impaction.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Cholinesterase Inhibitors for Dementia (Donepezil [Aricep], Rivastigmine, Galantamine): DIRECT PHARMACOLOGICAL CLASH! Solifenacin blocks muscarinic receptors while Donepezil boosts acetylcholine—co-administration worsens dementia and precipitates confusion! (Switch Solifenacin to Mirabegron in any patient taking Donepezil!)
- Potent CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, Ritonavir): Double Solifenacin plasma AUC—do NOT exceed 5 mg once daily! 3
- Additive Anticholinergic & QTc Burden: Amitriptyline, Tiotropium/Ipratropium, Antihistamines, Amiodarone, Domperidone
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: 1. Advise taking small sips of water or sucking sugar-free candy for dry mouth (rather than drinking huge 2-litre jugs of water at night, which worsens bladder frequency!). 2. Stop immediately and inform the doctor if urination becomes weak, painful, or stops completely. 3. During peak Indian summer heat (May–June), stay hydrated indoors, as solifenacin reduces sweating.
- Meal & Clock Timing Instruction: With or without food, swallowed whole with water. (Once daily (morning or evening; very long elimination half-life of 45–68 hours provides 24-hour bladder relaxation).)
- Missed Dose Protocol: Take the next scheduled tablet the following day; never take two tablets on the same day.
- Geriatric Dispensing Pearl: Beers Criteria Strong Caution: Antimuscarinic bladder drugs (Oxybutynin, Tolterodine, Solifenacin, Darifenacin) carry a high risk of confusion, falls, constipation, and dementia progression in elderly CGHS patients. In seniors >70 years or anyone with cognitive decline, Mirabegron (a Beta-3 agonist with zero anticholinergic cognitive toxicity) is generally preferred.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 5 mg, 10 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.3] (p. 156)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.10]-C158 Flavoxate Hydrochloride — Competitive Muscarinic (M2/M3) Receptor Antagonists & Direct Smoo
- [12.10]-CMP159 Drotaverine Hydrochloride IP — Competitive Muscarinic (M2/M3) Receptor Antagonists & Direct Smoo
- [12.11]-C160 Disodium Hydrogen Citrate — Systemic & Urinary Alkalinisers / Urolithiasis Inhibitors
- [12.11]-CMP161 Phenazopyridine Hydrochloride IP — Systemic & Urinary Alkalinisers / Urolithiasis Inhibitors